RE: Your Point?23 Feb 2019 20:03
VAL401 has shown from an insignificant number of patients that 'Palliative stage patients could expect to see improvements in symptoms with the added benefit of improved survival prospects' There are other treatments available. The extract below is from the RNS dated 16/1/18:
Ariana's KEM® systematic analysis of the Quality of Life improvements identified relations providing further insight into VAL401:
· Multiple patients reported an improvement in pain, which on comparison to pharmacokinetic parameters was linked to high exposure to VAL401.
· Improvement in fatigue was associated with lower exposure.
· Patients regardless of responder status reported improvements in Quality of Life measures suggesting palliative effects of VAL401 treatment. Responders additionally observed anti-cancer (survival) benefit.
Dr Suzy Dilly, CEO of ValiSeek, commented: "This data advocates the potential for VAL401 in treating very late stage cancer patients in the palliative arena. It also advocates the potential for VAL401, in the as yet untested combinations with, both traditional chemotherapies and immune-oncology treatments. Palliative stage patients could expect to see improvements in symptoms with the added benefit of improved survival prospects. This encouraging 60% overall response rate seen in this first all-comer trial, provides a strong foundation for the next stage of clinical testing. The measure of immune competency of the treated patients was also a pleasingly unexpected addition to the results. In sum, we are very excited to see such good response rate for a condition with huge unmet medical need."
Sign In
Follow the stocks
